DANA-FARBER CANCER INSTITUTE, INC.;PETER MACCALLUM CANCER INSTITUTE
发明人:
申请号：
ARP160103015
公开号：
AR107500A1
申请日:
2016.09.30
申请国别(地区):
AR
年份:
2018
代理人:
摘要：
This provides a method for treating cancer in a Subject that needs IT,The Method comprises administering to the subject a therapeutically effective amount of an inhibitor of bromodomain； and an immune Modulator.The Method of claim claim 11: 9 or 10, where the inhibitor is jq1 bromodomain of formula (1) or a Salt, solvate, hydrate, Polymorph, co Crystal, taut u00f3mero, stereoisomer,Marked with Isotope derivative or pharmaceutically acceptable prodrug.The Method of claim 12: claims 9 or 10, where the inhibitor is y803 bromodomain of formula (2), or a Salt, solvate, hydrate, Polymorph, co Crystal, taut u00f3mero, stereoisomer,Marked with Isotope derivative or pharmaceutically acceptable prodrug.The Method of claim claim 13: 9 or 10, where the inhibitor CPI - 203 bromodomain is formula (3) or a Salt, solvate, hydrate, Polymorph, co Crystal, taut u00f3mero, stereoisomer,Marked with Isotope derivative or pharmaceutically acceptable prodrug.The Method of claim 14: any one of claims 1 to 8, where the inhibitor is dbet1 bromodomain of formula (4) or a Salt, solvate, hydrate, Polymorph, co Crystal, taut u00f3mero,Stereoisomer, marked with Isotope derivative or pharmaceutically acceptable prodrug.The Method of claim 17: Claims 15 or 16, where the inhibitor is bromodomain ibet - 151 formula (5), or a Salt, solvate, hydrate, Polymorph, co Crystal, taut u00f3mero,Stereoisomer, marked with Isotope derivative or pharmaceutically acceptable prodrug.The Method of claim claim 20: 18 or 19, where the inhibitor is bromodomain ibet - 762 formula (6), or a Salt, solvate, hydrate, Polymorph, co Crystal, taut u00f3mero,Stereoisomer, marked with Isotope derivative or pharmaceutically acceptable prodrug.The Method of claim claim 23: 21 or 22, where the inhibitor is bromodomain RVX - 208 formula (7), or a Salt, solvate, hydrate Polymorph, co Crystal, taut u00f3mero, stereoisomer,Marked with Isotope derivative or pharmaceutically acceptable prodrug.The Method of claim claim 37: 36, where the i
